Neurocrine’s Growing Sales, Profits Attracting Big Money

NBIX is a biopharmaceutical company that discovers, develops, and markets drugs to treat neurological and endocrine-related illnesses. The company’s product portfolio continues to grow after it received regulatory approval in April for Ingrezza Sprinkle capsules, a drug that treats adults afflicted by Huntington’s disease.

On the financial front, in March the company reported quarterly revenue of $515.3 million and a net profit of $43.4 million. As for the future, NBIX’s total sales are expected to jump more than 15% in fiscal 2024 and 2025, with projections eclipsing $2 billion. Per-share earnings in 2024 are slated to rise by 71% to $4.22 versus $2.47 last year.

It’s no wonder NBIX shares are up 9% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Neurocrine Shares in Demand

Institutional volumes reveal plenty. Recently, NBIX has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in NBIX shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Neurocrine.

Neurocrine Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, NBIX has had strong sales and earnings growth:

• 3-year sales growth rate (+22.2%)
• 3-year earnings growth rate (+16.8%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +48%.

Now it makes sense why the stock has been powering to new heights. NBIX has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Neurocrine has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when NBIX was a top pick…making the share price jump:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Neurocrine Price Prediction

The NBIX rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in NBIX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.